<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2016">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05134922</url>
  </required_header>
  <id_info>
    <org_study_id>CELC-G-001</org_study_id>
    <nct_id>NCT05134922</nct_id>
  </id_info>
  <brief_title>Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009</brief_title>
  <official_title>Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in a Celcuity-Sponsored Clinical Study (B2151009)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celcuity, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celcuity, Inc.</source>
  <brief_summary>
    <textblock>
      Continued access to treatment for subjects who continue benefit from therapy with gedatolisib&#xD;
      in combination with palbociclib, and fulvestrant or letrozole.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary purpose of this study is to provide continuing access to treatment for subjects&#xD;
      who continue benefit from therapy with gedatolisib in combination with palbociclib, and&#xD;
      fulvestrant or letrozole.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
  </expanded_access_info>
  <condition>Breast Neoplasm Malignant Female</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gedatolisib</intervention_name>
    <description>Gedatolisib is a potent, reversible dual inhibitor that selectively targets phosphoinositide 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in biochemical and cellular assays.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Currently enrolled in the B2151009 clinical study and benefiting from treatment with&#xD;
             gedatolisib in combination with other therapies as determined by the Investigator&#xD;
&#xD;
          2. Previously demonstrated compliance and are willing and able to comply with scheduled&#xD;
             visits, treatment plans, and other study procedures&#xD;
&#xD;
          3. No evidence of progressive disease, as determined by the Investigator&#xD;
&#xD;
          4. Provide written informed consent prior to enrolling and receiving treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Permanently discontinued from treatment in Study B2151009, or discontinued from Study&#xD;
             B2151009 for any reason&#xD;
&#xD;
          2. Women who are pregnant, intend to become pregnant, or nursing&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Jill Krause, MBA</last_name>
    <phone>844-310-3900</phone>
    <phone_ext>1</phone_ext>
    <email>jkrause@celcuity.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Erica Stringer-Reasor, MD</last_name>
      <email>esreasor@uabmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Anne F Schott, MD</last_name>
      <phone>734-936-6266</phone>
      <email>aschott@med.umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Robert Weslowski, MD</last_name>
      <email>robert.wesolowski@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Rachel Layman, MD</last_name>
      <email>rlayman@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Jennifer Specht, MD</last_name>
      <phone>206-606-6768</phone>
      <email>jspecht@uw.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 14, 2021</study_first_submitted>
  <study_first_submitted_qc>November 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2021</study_first_posted>
  <last_update_submitted>November 14, 2021</last_update_submitted>
  <last_update_submitted_qc>November 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gedatolisib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

